Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

Forecasting The Future: 5 Analyst Projections For NewAmsterdam Pharma

During the last three months, 5 analysts shared their evaluations of NewAmsterdam Pharma (NASDAQ:NAMS), revealing diverse outlooks from bullish to bearish.

Benzinga

4 Analysts Assess Amylyx Pharma: What You Need To Know

During the last three months, 4 analysts shared their evaluations of Amylyx Pharma (NASDAQ:AMLX), revealing diverse outlooks from bullish to bearish.

Benzinga

Warren Buffett's Portfolio Stock Kroger Pauses Buybacks For Albertsons Merger, Narrows FY24 Outlook

Kroger pauses share buybacks for the Albertsons merger, misses Q3 sales estimates, and narrows its FY24 EPS guidance.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Verint Systems Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket

Shares of Verint Systems Inc. (NASDAQ:VRNT) rose sharply in today's pre-market trading after the company reported a year-over-year increase in third-quarter financial results.

Benzinga

Danish Medical Marijuana Producer Stenocare To Launch Patented 10mg THC And 10mg CBD Oil In Norway

A publicly traded Danish medical marijuana operator Stenocare announced Monday the approval of its innovative product, Astrum 10-10, for sale in Norway. This milestone paves the way for more patients to access the benefits of medical cannabis treatment. Astrum 10-10 is expected to become available to patients within the next…

Benzinga

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.

Benzinga

Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump

Pharma companies lobby for changes to Medicare drug price rules, targeting a four-year delay for pills' eligibility. Critics warn it may hinder patient access and innovation.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Hemi Pharma for Sale: “Hemi Pharma for Sale: Advanced Supplements for Peak Performance”

The pursuit of peak performance-whether in athletics, academics, or day-to-day life-has led to an increased demand for supplements that deliver more than just marginal gains. This is where Hemi Pharma for Sale steps in, offering a game-changing ...

USA Today Sports Media Group

5 Analysts Assess PROCEPT BioRobotics: What You Need To Know

In the last three months, 5 analysts have published ratings on PROCEPT BioRobotics (NASDAQ:PRCT), offering a diverse range of perspectives from bullish to bearish.

Benzinga

PTC Therapeutics Signs Exclusive Global License And Collaboration Agreement With Novartis; PTC To Receive Upfront Payment Of $1B, Up To $1.9B In Development, Regulatory And Sales Milestones

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE:NVS), for its

Benzinga

Eli Lilly (LLY) vs. Catalent (CTLT): Which Pharma Stock Offers Better Returns?

The pharma industry is evolving rapidly due to the ever-rising healthcare needs and increasing demand for customized medicine and treatments worldwide. So, let’s analyze Eli Lilly (LLY) and Catalent (CTLT), to determine which pharma stock offers better returns. Read more.

StockNews.com

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

StockNews.com

3 Biotech ETFs for Diversified Innovation Exposure

Biotech ETFs provide the perfect balance of high-growth potential and diversified risk, offering investors access to healthcare breakthroughs. Given this backdrop, you might consider three biotech ETFs: iShares Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and First Trust NYSE Arca Biotechnology Index Fund (FBT). Keep reading….

StockNews.com

Telanagana: Spurious antibiotics worth Rs 1.33 crore seized from a pharmaceutical company

The drugs-control-administration">Drugs Control Administration, Telangana, seized a huge stock of antibiotics worth Rs 1.33 Crores from a manufacturing facility on Wednesday. Read further on Dynamite News:

Dynamite News

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Regeneron Pharmaceuticals Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).

Benzinga

AMD Struggles Below Critical Levels: Can Market Share Growth Turn The Tide?

AMD stock faces bearish wave, below key moving averages with neutral RSI. Short-term rebound possible, but overall technicals and market share gains uncertain.

Benzinga

Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details

Roche agrees to acquire Poseida Therapeutics for $1.5 billion, expanding its CAR-T therapy platform with a focus on hematologic malignancies and solid tumors.

Benzinga

Milestone Scientific Secures Federal Supply Schedule Approval On Contract For CompuFlo Epidural System

Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced its approval on contract for the Federal Supply Schedule

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

4 Analysts Assess Enanta Pharma: What You Need To Know

In the last three months, 4 analysts have published ratings on Enanta Pharma (NASDAQ:ENTA), offering a diverse range of perspectives from bullish to bearish.

Benzinga

Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket

Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) rose sharply in today's pre-market trading after the company agreed to be acquired by Roche in a $1.5 billion deal.

Benzinga

AIM ImmunoTech Issues Presentation Detailing Case For Re-Electing Current Directors To Oversee Continued Momentum And Drive Strategy To Create Long-Term Value For Patients And Shareholders; Warns Shareholders Of Its Belief That The Activist Group And Its Nominees Have A Self-Interested Agenda And Could Put AIM's Clinical Progress At Risk

Highlights How Positive Data in AIM's Clinical Pipeline and Big Pharma Partnerships are Positioning the Company for Commercialization Opportunities in High-Value Indications Including Pancreatic CancerWarns Shareholders

Benzinga

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts

Rhythm Pharmaceuticals (NASDAQ:RYTM) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

Benzinga

Analyst Expectations For Sarepta Therapeutics's Future

14 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Creative Bloq

I love the ingenious design of this women’s health brand logo

Design Bridge and Partners create a pioneering brand for the future.

Salon

Democrats can still lower drug prices

High medication costs are a common enemy for Democrats, Republicans and patients. There's still time to fight

1 … 26 27 28 29

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.